MétaCan
Menu
← Back to cohort
Record W4416556432 · doi:10.1016/j.ijrobp.2025.11.005

Stereotactic Body Radiation Therapy for Renal Tumors: A Prospective Phase 2 Clinical Trial

2025· article· en· W4416556432 on OpenAlexafffund
Rachel Glicksman, Jeff D. Winter, Andrew McPartlin, Anna Santiago, Jennifer Dang, Grace Tsui, Peter Chung, Aruz Mesci, Srinivas Raman, Alejandro Berlín, Charles Catton, Andrew Bayley, Padraig Warde, Satheesh Krishna, Antonio Finelli, Robert J. Hamilton, Kenneth T. Pace, Abhijat Kitchlu, Joelle Helou

Bibliographic record

VenueInternational Journal of Radiation Oncology*Biology*Physics · 2025
Typearticle
Languageen
FieldMedicine
TopicRenal cell carcinoma treatment
Canadian institutionsWestern UniversitySt. Michael's HospitalUniversity Health NetworkUniversity of TorontoPrincess Margaret Cancer CentreBC Cancer AgencyUniversity of British Columbia
FundersJanssen CanadaAbbVieSanofiAstraZenecaAstellas PharmaAstellas Pharma USAmgen CanadaAmgen
KeywordsClinical trialRadiation therapyRenal functionPhases of clinical researchPhase (matter)

Abstract

fetched live from OpenAlex

Background Stereotactic body radiotherapy (SBRT) represents a novel, efficacious treatment for patients with kidney tumors who are medically inoperable or decline surgery. There is limited prospective data on the impact of kidney SBRT on renal function. Methods This was a prospective phase II single-arm clinical trial (clinicaltrials.gov NCT03747133) of kidney-directed SBRT in patients with primary or metastatic renal lesions who were medically inoperable or declined surgery. The primary outcome was change in kidney function, assessed by change in eGFR over 2 years. The a priori hypothesis was that eGFR (mL/min/1.73m 2 ) does not decrease over time and was analyzed using a one sample t-test for non-inferiority with a fixed margin of -6.974 based on published data at time of trial design. Results Thirty patients with 32 renal tumors enrolled, with median (IQR) age 76 (73-82), Charlson comorbidity index 8 (7-9), 93% with chronic kidney disease (CKD) stage ≥2 (eGFR ≤60 mL/min/1.73 m 2 ), and majority with cT1b disease with median tumor size 43 mm. Twenty-six patients (87%) had primary kidney cancer, and the remainder had non-kidney cancer metastatic lesions. Median radiation dose was 35 Gy in 5 fractions. Median follow-up was 24.5 months (IQR 20-36.2). Median (IQR) eGFR levels (mL/min/1.73m 2 ) were 47.5 (37.8-64.0) at baseline, 42.0 (35.2-54.2) at 1-year and 39.5 (25.5-54.8) at 2-years. Eighteen of thirty patients were evaluable for eGFR at 2-years. Non-inferiority was not established based on a mean reduction in eGFR between baseline and 2 years of -8.7 mL/min/1.73m 2 (95% one-sided CI -14.1, ∞; p=0.71). Renal function decline was significantly associated with time, increasing age, baseline CKD stage 3-4, and larger baseline tumor size on multivariable analysis. Local control was 96.7% at 2 years. Conclusions Kidney-directed SBRT results in modest clinical renal function loss up to 2-years following SBRT, based on evaluable patients in our study. Technical advances may further improve the therapeutic ratio.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.007
Threshold uncertainty score0.023

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.001
Meta-epidemiology (narrow)0.0030.001
Meta-epidemiology (broad)0.0030.002
Bibliometrics0.0010.001
Science and technology studies0.0010.002
Scholarly communication0.0020.001
Open science0.0010.001
Research integrity0.0020.004
Insufficient payload (model declined to judge)0.0070.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.052
GPT teacher head0.429
Teacher spread0.377 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes2
Has abstractno

Explore more

Same venueInternational Journal of Radiation Oncology*Biology*Physics→Same topicRenal cell carcinoma treatment→French-language works237,207→